Autoimmune Disease Summit 2026
Media Partnership
Among Immune Discovery, iMed and 4th Cell Therapy for Autoimmune Disease Summi
Life science organizations developing cell therapies for autoimmune diseases are under increasing pressure to translate promising clinical results into scalable, commercially viable treatments. While early proof-of-concept studies have demonstrated the transformative potential of approaches such as CAR-T, NK, Treg, MSC, and emerging in vivo therapies, significant challenges remain in target selection, manufacturing scalability, safety management, regulatory alignment, and patient accessibility. As clinical datasets mature and the field expands beyond oncology, developers must establish clear strategies to accelerate development, demonstrate long-term value, and deliver meaningful outcomes for patients. The 4th Cell Therapy for Autoimmune Disease Summit brings together industry leaders to share real-world insights, benchmark best practices, and foster collaborations that will help advance the next generation of autoimmune cell therapies from clinical promise to widespread patient impact.
Among Immune Discovery, iMed and 4th Cell Therapy for Autoimmune Disease Summi
Life science organizations developing cell therapies for autoimmune diseases are under increasing pressure to translate promising clinical results into scalable, commercially viable treatments. While early proof-of-concept studies have demonstrated the transformative potential of approaches such as CAR-T, NK, Treg, MSC, and emerging in vivo therapies, significant challenges remain in target selection, manufacturing scalability, safety management, regulatory alignment, and patient accessibility. As clinical datasets mature and the field expands beyond oncology, developers must establish clear strategies to accelerate development, demonstrate long-term value, and deliver meaningful outcomes for patients. The 4th Cell Therapy for Autoimmune Disease Summit brings together industry leaders to share real-world insights, benchmark best practices, and foster collaborations that will help advance the next generation of autoimmune cell therapies from clinical promise to widespread patient impact.